Latest Market Access News

Lakes Blue Energy NL has resumed trading on the ASX following a suspension tied to a recent capital raising announcement, signaling renewed investor access and potential financial shifts.

Metallium Ltd, formerly MTM Critical Metals, has upgraded its U.S. listing to the OTCQX Best Market, enhancing investor access and aligning with its expanding U.S. operations including a new Texas commercial site.

Proteomics International has secured a dedicated US reimbursement code for its next-generation PromarkerD test, a key step towards broader adoption in diabetic kidney disease diagnostics.

EMVision Medical Devices has activated five of six pivotal trial sites for its emu™ bedside brain scanner, advancing towards FDA clearance while launching a parallel innovation study in Australia.

James Hardie Industries has completed its $8.4 billion acquisition of The AZEK Company, creating a powerhouse in exterior home and outdoor living solutions. The merger promises accelerated growth, significant synergies, and a broadened global footprint.

Findi Limited’s shares have been suspended from trading on the ASX starting 1 July 2025 due to failure to lodge a required periodic report on time. The suspension will remain until the report is submitted and trading can resume.

New Murchison Gold Limited has secured all key approvals and mobilised equipment for mining at its Crown Prince Gold Project, with first ore delivery expected by September 2025. The company also announced a $15 million capital raise to support its transition from explorer to producer.

AIC Mines has locked in a US$40 million prepayment facility tied to a copper offtake agreement with Trafigura, aiming to boost processing capacity at its Eloise mine.

New World Resources Limited has had its trading suspension lifted immediately following a key announcement, reopening market access for investors.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.

Lumos Diagnostics has enrolled 500 patients in its FebriDx CLIA waiver clinical study, unlocking a significant milestone payment from BARDA and moving closer to FDA approval that could open a US$1 billion market.

Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.